Journal article
Are biologics for chronic rhinosinusitis effective and safe?
- Abstract:
- Chronic rhinosinusitis (CRS) refers to inflammation of the nasal sinuses and mucosa, with persistence of sinus inflammation and clinical manifestations beyond 12 weeks.1 CRS affects between 6 and 12% of adults and is a cause of reduced quality of life (QoL) and high healthcare costs.2 Management consisted of topical and systemic glucocorticoids, antibiotics and often repeated sinus surgery. Over the past 20 years, biologic therapies under investigation for asthma, with overlapping nasal polyposis, have shown significant improvement in sinonasal CRS symptoms and reduced nasal polyp swelling.3 This Cochrane Corner aims to summarize the effectiveness, safety and role of biological therapy in CRS to aid clinicians in the decision-making process.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, 226.0KB, Terms of use)
-
- Publisher copy:
- 10.1111/cea.13904
Authors
- Publisher:
- Wiley
- Journal:
- Clinical and Experimental Allergy More from this journal
- Volume:
- 51
- Issue:
- 7
- Pages:
- 870-872
- Publication date:
- 2021-06-11
- Acceptance date:
- 2021-05-14
- DOI:
- EISSN:
-
1365-2222
- ISSN:
-
0954-7894
- Language:
-
English
- Keywords:
- Pubs id:
-
1176374
- Local pid:
-
pubs:1176374
- Deposit date:
-
2021-05-14
Terms of use
- Copyright holder:
- John Wiley & Sons Ltd.
- Copyright date:
- 2021
- Rights statement:
- © 2021 John Wiley & Sons Ltd.
- Notes:
-
This is the accepted manuscript version of the article. The final version is available from Wiley at https://doi.org/10.1111/cea.13904
If you are the owner of this record, you can report an update to it here: Report update to this record